


PRODUCT INFORMATION



Darifenacin (hydrobromide)

Item No. 14424

CAS Registry No.: 133099-07-7
Formal Name: 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-
 α,α -diphenyl-3-pyrrolidineacetamide,
monohydrobromide
Synonym: UK 88525-04
MF: $C_{28}H_{30}N_2O_2 \cdot HBr$
FW: 507.5
Purity: $\geq 95\%$
UV/Vis.: λ_{max} : 205, 287 nm
Supplied as: A crystalline solid
Storage: $-20^\circ C$
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Darifenacin (hydrobromide) is supplied as a crystalline solid. A stock solution may be made by dissolving the darifenacin (hydrobromide) in the solvent of choice, which should be purged with an inert gas. Darifenacin (hydrobromide) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of darifenacin (hydrobromide) in these solvents is approximately 0.3, 2, and 3 mg/ml, respectively.

Darifenacin (hydrobromide) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, darifenacin (hydrobromide) should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Darifenacin (hydrobromide) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Darifenacin is an antagonist of M_3 muscarinic acetylcholine receptors (mAChRs; $K_i = 0.76$ nM).¹ It is selective for M_3 over M_1 , M_2 , M_4 , and M_5 mAChRs (K_i s = 7.08, 44.67, 45.71, and 9.33 nM, respectively). Darifenacin selectively inhibits contractions in isolated guinea pig ileum, bladder, and trachea ($pA_{2.5}$ = 9.44, 8.66, and 8.7, respectively), tissues that endogenously express high levels of M_3 mAChRs, over isolated rabbit vas deferens and isolated guinea pig atria ($pA_{2.5}$ = 7.9 and 7.48, respectively), which endogenously express M_1 and M_2 mAChRs, respectively. It inhibits micturition pressure ($ED_{50} = 0.089$ mg/kg, i.v.), as well as micturition interval and volume in rats. Formulations containing darifenacin have been used in the treatment of overactive bladder.

References

1. Wallis, R.M. and Napier, C.M. Muscarinic antagonists in development for disorders of smooth muscle function. *Life Sci.* **64**(6-7), 395-401 (1999).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/03/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM